DE-126 (OTX-TIC)
Primary Open-Angle Glaucoma & Ocular Hypertension
Phase 3Active
Key Facts
Indication
Primary Open-Angle Glaucoma & Ocular Hypertension
Phase
Phase 3
Status
Active
Company
About Santen Pharmaceutical
Santen's mission is to contribute to the well-being of patients, society, and employees by addressing ophthalmic diseases through specialized innovation. The company has achieved a leading global position in ophthalmology with a robust commercial portfolio and a deep R&D pipeline focused on glaucoma, retinal diseases, and ocular surface disorders. Its strategy is built on a vertically integrated, ophthalmology-focused model that enables deep expertise, operational efficiency, and targeted global expansion in both developed and emerging markets.
View full company profile